Cenicriviroc (CVC) is currently in clinical development for non-alcoholic steatohepatitis (NASH) in adults with liver fibrosis and primary sclerosing cholangitis (PSC).
Over 600 unique subjects have been exposed to CVC in completed studies, including 440 subjects participating in Phase 1 studies and 159 HIV infected subjects participating in Phase 2 studies.
CVC is a dual inhibitor of the CCR2 and CCR5 pathways which play a key role in the cycle of inflammation and fibrosis. CVC has been shown in clinical trials to bind to both CCR2 and CCR5 targets.
Mechanism of Action
Immune and inflammatory response to liver cell damage is mediated through a well-described signaling network of liver and immune cells. An accumulation of fat in the liver causes injury, and Kupffer cells sense the tissue injury and are the first responders to liver cell damage. Activated Kupffer cells initiate an inflammatory response to the liver injury. Ultimately, Kupffer cells and other pro-inflammatory macrophages activate hepatic stellate cells that differentiate into cells responsible for liver fibrosis. The CCR2 and CCR5 signaling pathways play a central role throughout this process.